Raymond James reiterates Strong Buy rating and $68 target on Liquidia after the Supreme Court’s positive Hikma v. Amarin decision.

Reported Monday, Sep 21 - 12:35pm EDT (TheFly subscription required to read more.)

Achieved YUTREPIA ® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter More than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025 Ended 2025 with $190.7 million in cash and cash equivalents, an increase

By Kevin E. Noonan -- United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations of treprostinil (UTC's Tyvaso®,...

Reported Thursday, Sep 3 - 7:34am EDT (TheFly subscription required to read more.)

Click to view the official SEC document.

Liquidia (LQDA) received U.S. FDA Fast Track designation for YUTREPIA (treprostinil) inhalation powder to treat Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). Fast Track status is intended for serious conditions with unmet medical need and may enable more frequent FDA interactions and rolling review.SSc-RP affects up to 90% of systemic sclerosis patients, with 40%–60% developing digital ischemic ulcers and some progressing to amputation. No therapy is currently FDA-approved specifically for SSc-RP. Liquidia estimates about 30,000 U.S. patients have moderate to severe SSc-RP symptoms.Liquidia plans to start RE-WARM (NCT07748000), a Phase 2a, randomized, open-label, dose-finding study of YUTREPIA in approximately 75 adults with SSc-RP at up to 30 U.S. sites. The study is expected to begin in October 2026 with primary completion targeted for February 2027 and will assess safety, pharmacodynamics and exploratory effects on attack frequency, severity and impact.

What Liquidia Corp changed in their own words, quarter over quarter.

Liquidia (NASDAQ:LQDA – Get Free Report) had its target price raised by equities research analysts at Needham & Company LLC from $70.00 to $110.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price target would suggest a potential upside of 52.57% [...]

Liquidia (NASDAQ:LQDA) reported strong second quarter 2026 results driven by YUTREPIA (treprostinil) inhalation powder, with net product sales of approximately $170.4 million, up 31% from the first quarter of 2026, and its fourth consecutive quarter of profitability.Total Q2 2026 revenue reached $171.7 million versus $8.8 million a year earlier, generating net income of $74.7 million and non-GAAP adjusted EBITDA of $96.3 million. Cash and cash equivalents increased to $284.2 million at June 30, 2026, from $190.7 million at December 31, 2025. Since launch in June 2025, YUTREPIA has received about 5,900 unique prescriptions, started treatment for more than 5,000 patients, with prescription-to-start conversion above 85%, and over 1,100 prescribers, while the company advances 10 clinical studies for YUTREPIA and L606.